Overview

DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Status:
Completed

Trial end date:
2019-12-31

Target enrollment:

Participant gender:

Summary

Both DCb (docetaxel/carboplatin) and EC followed by D (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety of DCb (docetaxel/carboplatin) and EC followed by D(epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment in Triple-Negative breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.

Phase:

Phase 2

Details

Lead Sponsor:

Guangdong General Hospital
Guangdong Provincial People's Hospital

Collaborators:

Baotou Cancer Hospital
Dongguan People's Hospital
First Affiliated Hospital, Sun Yat-Sen University
Henan Cancer Hospital
Shantou Central Hospital

Treatments:

Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin